ESSA Pharma Inc.

NasdaqCM:EPIX Stock Report

Market Cap: US$71.5m

ESSA Pharma Management

Management criteria checks 4/4

ESSA Pharma's CEO is David Parkinson, appointed in Jan 2016, has a tenure of 8.92 years. total yearly compensation is $814.15K, comprised of 70.9% salary and 29.1% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $105.88K. The average tenure of the management team and the board of directors is 8.6 years and 5.5 years respectively.

Key information

David Parkinson

Chief executive officer

US$814.2k

Total compensation

CEO salary percentage70.9%
CEO tenure8.9yrs
CEO ownership0.1%
Management average tenure8.6yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

Aug 21
Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

Feb 18
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

Aug 16
ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Jan 25
Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

Dec 15
We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen

Feb 02

ESSA Pharma and Janssen to test combo treatments in prostate cancer setting

Jan 13

ESSA Pharma EPS beats by $0.02

Dec 15

CEO Compensation Analysis

How has David Parkinson's remuneration changed compared to ESSA Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$29m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023n/an/a

-US$26m

Sep 30 2023US$814kUS$578k

-US$27m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022n/an/a

-US$33m

Sep 30 2022US$922kUS$549k

-US$35m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$37m

Dec 31 2021n/an/a

-US$39m

Sep 30 2021US$2mUS$518k

-US$37m

Jun 30 2021n/an/a

-US$33m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020n/an/a

-US$25m

Sep 30 2020US$3mUS$492k

-US$23m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019n/an/a

-US$15m

Sep 30 2019US$996kUS$469k

-US$13m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$11m

Dec 31 2018n/an/a

-US$12m

Sep 30 2018US$1mUS$446k

-US$12m

Compensation vs Market: David's total compensation ($USD814.15K) is about average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Parkinson (74 yo)

8.9yrs

Tenure

US$814,152

Compensation

Dr. David Ross Parkinson, M.D., has been a Director of Realm Therapeutics plc. since July 31, 2019. He serves as Member of Advisory Board at AsedaSciences Inc. Dr. Parkinson had been an Independent Directo...

Leadership Team

NamePositionTenureCompensationOwnership
David Parkinson
President8.9yrsUS$814.15k0.15%
$ 105.9k
David Wood
Chief Financial Officer11.4yrsUS$590.39k0.075%
$ 53.7k
Peter Virsik
Executive VP & COO8.3yrsUS$645.95k0.018%
$ 12.5k
Alessandra Cesano
Chief Medical Officer & Executive VP5.4yrsUS$623.93k0.012%
$ 8.2k
Chandtip Chandhasin
Executiveno datano datano data
Erica Osbourne
Executiveno datano datano data
Erin Rudsinski
Executiveno datano datano data
Loleta Harris
Executiveno datano datano data
Neil Thapar
Executiveno datano datano data
Nkengyal Barber
Executiveno datano datano data
Steve Pondell
Executiveno datano datano data
Terry Schuenemeyer
Executiveno datano datano data

8.6yrs

Average Tenure

65.5yo

Average Age

Experienced Management: EPIX's management team is seasoned and experienced (8.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Parkinson
President9.5yrsUS$814.15k0.15%
$ 105.9k
Sanford Zweifach
Independent Director5.4yrsUS$48.00k0%
$ 0
Richard Glickman
Independent Chairman of the Board14.2yrsUS$70.00k0.097%
$ 69.6k
Gary Sollis
Independent Director12.7yrsUS$50.00k0%
$ 0
John Martin
Independent Director5.4yrsUS$35.00k0.032%
$ 23.0k
Franklin Berger
Independent Director9.8yrsUS$54.00k1.77%
$ 1.3m
Scott Requadt
Independent Director8.9yrsUS$47.00k0.068%
$ 48.3k
Philip Kantoff
Independent Director2.3yrsUS$35.00k0%
$ 0
Marella Thorell
Independent Director5.4yrsUS$42.00k0.0065%
$ 4.6k
Marianne Sadar
Scientific Advisor5.5yrsUS$229.20kno data
Raymond Andersen
Scientific Advisorno dataUS$229.20kno data
Lauren Merendino
Independent Director1.5yrsUS$162.67k0%
$ 0

5.5yrs

Average Tenure

67yo

Average Age

Experienced Board: EPIX's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:58
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ESSA Pharma Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Maurice RaycroftJefferies LLC
Soumit RoyJonesTrading Institutional Services, LLC